Skip to main content
NVDA-1.19%AAPL+0.67%GOOGL-2.28%MSFT-0.48%AMZN-0.82%TSM-0.83%SPCX-3.86%AVGO-1.13%META+0.20%TSLA-1.97%SKHY+7.05%MU-3.05%BRK-B+0.18%LLY+0.02%JPM+0.34%AMD+3.04%WMT-0.21%V-0.34%XOM+2.24%ASMLa-2.91%JNJ-0.76%INTC+1.69%MA-0.59%0700.HK-1.94%ORCL-0.50%1398.HK+0.79%BAC+0.45%ABBV+0.88%CSCO+0.24%CVX+1.91%COST-0.83%LRCX-1.43%KO-0.92%CAT-0.84%AMAT-0.83%0005.HK-0.78%AP2d-2.69%UNH-1.94%DELL+0.29%HSBA.L-1.34%MS-0.42%PG-2.02%GE-2.83%3988.HK+0.84%1816.HK+0.23%0857.HK-3.26%NFLX-0.96%HD-1.04%GS-0.75%0939.HK+1.66%NZDJPY-2.62%AUDJPY-1.87%CHFJPY-1.71%NZDCAD-1.45%GBPJPY-1.39%EURJPY-1.38%NZDUSD-1.37%EURNZD+1.28%USDJPY-1.28%GBPNZD+1.24%CADJPY-1.19%NZDCHF-0.95%USDZAR+0.95%USDSEK+0.88%USDNOK+0.87%AUDNZD+0.78%AUDCAD-0.72%EURZAR+0.67%USDTHB+0.61%USDMXN+0.61%AUDUSD-0.61%EURSEK+0.60%GBPZAR+0.59%EURNOK+0.59%AUDSGD-0.54%USDPLN+0.53%AUDDKK-0.52%CADCHF+0.51%EURAUD+0.50%CHFSEK+0.49%CHFNOK+0.48%GBPAUD+0.47%USDCHF+0.45%GBPTRY+0.41%NOKJPY-0.41%NZDSGD-0.38%GBPHKD+0.32%EURCHF+0.32%GBPCHF+0.30%EURHKD-0.30%GBPMXN-0.28%USDDKK+0.28%USDSGD+0.27%EURPLN+0.25%GBPCAD-0.22%EURCAD-0.20%SGDJPY+0.19%EURCNH-0.17%AUDCHF-0.17%USDILS+0.16%CHFSGD-0.12%GBPUSD-0.12%EURUSD-0.12%USDTRY+0.11%USDCNH+0.09%GBPSGD-0.09%USDCAD-0.08%PLNJPY-0.07%NZDMXN-0.06%AUDNOK+0.06%USDCOP-0.04%EURCZK-0.03%EURGBP+0.03%EURSGD-0.01%USDHKD+0.01%EURDKK0.00%XPTUSD-4.86%XAGUSD-4.32%GAGUSD-4.32%HG1-4.09%UKOIL+3.27%USOIL+3.15%COFFEE-2.45%GAUUSD-1.17%XAUUSD-1.17%SUGAR+1.15%COTTON+0.60%XNGUSD-0.29%BTCUSD-1.81%ETHUSD-2.01%USDTUSD-0.02%XRPUSD-2.77%SOLUSD-2.07%TRXUSDT-0.17%ZECUSDT-5.51%DOGEUSD-2.88%XMRUSDT-2.04%LINKUSD-1.08%XLMUSD-2.10%BCHUSDT-8.60%LTCUSD-2.09%UNIUSD-4.73%TONUSD+24.88%HBARUSDT-2.37%SUIUSD-2.75%TAOUSDT-4.55%AAVEUSD-3.25%DOTUSDT-2.63%ICPUSDT-1.30%ONDOUSDT-2.87%WLDUSDT-2.43%ATOMUSDT-3.41%ARBUSDT-1.04%JUPUSDT-3.82%INJUSDT-3.30%STXUSDT-3.80%FETUSDT-3.24%TIAUSDT-1.65%SEIUSDT-3.91%PYTHUSDT-1.17%IMXUSDT-3.06%WIFUSDT-4.40%GRTUSDT-3.82%OPUSDT-3.00%IOTAUSDT-3.80%POLUSDT-7.08%AXSUSDT-2.57%FARTCOINUSDT-3.67%EOSUSDT-1.86%DYDXUSDT-0.24%ORDIUSDT-0.69%GALAUSDT-4.78%NOTUSDT-0.68%RONINUSDT-2.64%NVDA-1.19%AAPL+0.67%GOOGL-2.28%MSFT-0.48%AMZN-0.82%TSM-0.83%SPCX-3.86%AVGO-1.13%META+0.20%TSLA-1.97%SKHY+7.05%MU-3.05%BRK-B+0.18%LLY+0.02%JPM+0.34%AMD+3.04%WMT-0.21%V-0.34%XOM+2.24%ASMLa-2.91%JNJ-0.76%INTC+1.69%MA-0.59%0700.HK-1.94%ORCL-0.50%1398.HK+0.79%BAC+0.45%ABBV+0.88%CSCO+0.24%CVX+1.91%COST-0.83%LRCX-1.43%KO-0.92%CAT-0.84%AMAT-0.83%0005.HK-0.78%AP2d-2.69%UNH-1.94%DELL+0.29%HSBA.L-1.34%MS-0.42%PG-2.02%GE-2.83%3988.HK+0.84%1816.HK+0.23%0857.HK-3.26%NFLX-0.96%HD-1.04%GS-0.75%0939.HK+1.66%NZDJPY-2.62%AUDJPY-1.87%CHFJPY-1.71%NZDCAD-1.45%GBPJPY-1.39%EURJPY-1.38%NZDUSD-1.37%EURNZD+1.28%USDJPY-1.28%GBPNZD+1.24%CADJPY-1.19%NZDCHF-0.95%USDZAR+0.95%USDSEK+0.88%USDNOK+0.87%AUDNZD+0.78%AUDCAD-0.72%EURZAR+0.67%USDTHB+0.61%USDMXN+0.61%AUDUSD-0.61%EURSEK+0.60%GBPZAR+0.59%EURNOK+0.59%AUDSGD-0.54%USDPLN+0.53%AUDDKK-0.52%CADCHF+0.51%EURAUD+0.50%CHFSEK+0.49%CHFNOK+0.48%GBPAUD+0.47%USDCHF+0.45%GBPTRY+0.41%NOKJPY-0.41%NZDSGD-0.38%GBPHKD+0.32%EURCHF+0.32%GBPCHF+0.30%EURHKD-0.30%GBPMXN-0.28%USDDKK+0.28%USDSGD+0.27%EURPLN+0.25%GBPCAD-0.22%EURCAD-0.20%SGDJPY+0.19%EURCNH-0.17%AUDCHF-0.17%USDILS+0.16%CHFSGD-0.12%GBPUSD-0.12%EURUSD-0.12%USDTRY+0.11%USDCNH+0.09%GBPSGD-0.09%USDCAD-0.08%PLNJPY-0.07%NZDMXN-0.06%AUDNOK+0.06%USDCOP-0.04%EURCZK-0.03%EURGBP+0.03%EURSGD-0.01%USDHKD+0.01%EURDKK0.00%XPTUSD-4.86%XAGUSD-4.32%GAGUSD-4.32%HG1-4.09%UKOIL+3.27%USOIL+3.15%COFFEE-2.45%GAUUSD-1.17%XAUUSD-1.17%SUGAR+1.15%COTTON+0.60%XNGUSD-0.29%BTCUSD-1.81%ETHUSD-2.01%USDTUSD-0.02%XRPUSD-2.77%SOLUSD-2.07%TRXUSDT-0.17%ZECUSDT-5.51%DOGEUSD-2.88%XMRUSDT-2.04%LINKUSD-1.08%XLMUSD-2.10%BCHUSDT-8.60%LTCUSD-2.09%UNIUSD-4.73%TONUSD+24.88%HBARUSDT-2.37%SUIUSD-2.75%TAOUSDT-4.55%AAVEUSD-3.25%DOTUSDT-2.63%ICPUSDT-1.30%ONDOUSDT-2.87%WLDUSDT-2.43%ATOMUSDT-3.41%ARBUSDT-1.04%JUPUSDT-3.82%INJUSDT-3.30%STXUSDT-3.80%FETUSDT-3.24%TIAUSDT-1.65%SEIUSDT-3.91%PYTHUSDT-1.17%IMXUSDT-3.06%WIFUSDT-4.40%GRTUSDT-3.82%OPUSDT-3.00%IOTAUSDT-3.80%POLUSDT-7.08%AXSUSDT-2.57%FARTCOINUSDT-3.67%EOSUSDT-1.86%DYDXUSDT-0.24%ORDIUSDT-0.69%GALAUSDT-4.78%NOTUSDT-0.68%RONINUSDT-2.64%
ST

Stoke Therapeutics, Inc. (STOK)

NASDAQ • Healthcare

$29.92
-$0.12 (-0.4%)
Market open

Last close at September 9, 2026 at 20:00 UTC

Open$29.53
Previous Close$29.92
Day Range$29.53 - $30.53
Avg. Volume (3M)819.6K
Market Cap$1.9B
52 Week Range
$20.32$40.22
Next EarningsIn 54 daysNov 3, 2026

Metrics Over Time

Where the Money Goes

Q2 2026
Revenueeverything earned$9.3M100%
Gross Profitminus cost of goods$8.1M88%

Fundamentals & Financials

Revenue (TTM)
$27.5M
Net Income (TTM)
-$207.9M
EPS (TTM)
-$3.36
ROA (TTM)
-52.77%
Current Ratio
7.69

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Earnings

-29.3%Q1 2026-$0.97
+1.3%Q2 2026-$0.79
-17.0%Q3 2026-$0.93
Next

Nov 3

in 54 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q3 2026
Miss -17.0%

Stoke Therapeutics’ second fiscal quarter of 2026 results missed expectations on earnings, with EPS of -$0.93 trailing the -$0.80 estimate (difference -$0.14), as reported August 3, 2026. Revenue fell 33% to about $9.3 million from $13.8 million a year ago, alongside a net loss of roughly $61.6 million versus -$23.5 million a year ago, and operating income came in at around -$65.4 million as the company continued advancing its RNA-based medicines pipeline, including programs built on its TANGO platform. On a per-share basis, EPS was down 132% year over year from -$0.40, consistent with the wider net loss over the period. For the next period, consensus calls for EPS of -$0.88 on revenue of $8.2 million.

View full earnings history

About Stoke Therapeutics, Inc.

Stoke Therapeutics, Inc. develops RNA-based medicines in biotechnology and trades on the NASDAQ under STOK. The company focuses on antisense oligonucleotide therapies built to raise protein expression through its TANGO platform, which engineers ASOs to enhance protein expression, and it recorded $184.4 million in revenue in FY2025.

Name
Stoke Therapeutics, Inc.
CEO
Ian F. Smith
Website
www.stoketherapeutics.com
Industry
Healthcare
Year Founded
2014
Employees
170

Today's Snapshot

AI-generated

Yesterday STOK finished slightly down at 29.92. Goldman Sachs, an investment bank, reiterated its rating on Stoke Therapeutics, citing confidence in its epilepsy study.

Trading Volume

Below 10d avg (789.7K)

639.8K

vs S&P 500 Today

Inline with Market

+0.05%

Updated: September 10, 2026 at 12:22 UTC

Technical Indicators

1 Buy1 Neutral6 Sell
STOK’s profile is tilted toward weakness, with momentum and oscillator measures showing downside bias while trend strength remains muted. CCI and MACD are negative and momentum is declining, and the stock is trading below its short- and medium-term moving averages as well as the 200-day series, signaling that recent price action favors sellers. ADX around 16 indicates limited trend conviction and ATR near 1.47 points to moderate volatility, while the pivot sits close to the current price of 29.92. Technical takeaway: Sell — short-term selling undercuts the outlook amid only modest trend confirmation.
All signals
  • EMA (5 indicators)$30.70 - $31.29
    Sell
  • RSI (14)40.92
    Neutral
  • Stochastic %K (14, 3, 3)19.05
    Buy
  • MACD Level (12, 26)-0.31
    Sell

Peers & Related Assets

SYRESpyre Therapeutics, Inc.
$86.93-4.3%
BCRXBioCryst Pharmaceuticals, Inc.
$8.81-2.9%
ZBIOZenas BioPharma, Inc.
$32.29-2.3%
ZYMEZymeworks Inc.
$27.15-3.4%
NTLAIntellia Therapeutics, Inc.
$12.21-4.2%
NVAXNovavax, Inc.
$9.85-3.3%
Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.